Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future
Chemical modification of chitosan-based nanostructures can improve their ability to heal wounds and interact with particular ligands, substances, or biomolecules
Minimize handling : Every time you access a peptide vial, you expose it to ambient conditions
Microwave frequency electromagnetic fields (EMFs) produce widespread neuropsychiatric effects including depression
Our West Los Angeles team will follow up within one business day
Forma activa: La levocarnitina es la forma biolgicamente activa que el cuerpo absorbe y utiliza de manera eficiente